 For the first 28 day cycle, all patients will be treated with single agent pacritinib at 200 mg twice daily. The investigators chose this starting dose based on the previous three phase I studies of pacritinib as a single agent which showed that the maximum tolerated dose MTD to be 500 mg, and subsequently, the dose of 400 mg daily was recommended for the phase II studies. 